

# CHINA FOCUS @ BIO PHILADELPHIA

## CHINA FOCUS

Loews Philadelphia Hotel  
1200 Market St  
Philadelphia, PA 19107

JUNE 02  
2019



: ORGANIZER




: GOLD SPONSOR



: SILVER SPONSOR


# DIRECTION

## Second floor



	Theme	Location	Time
<b>Track 1</b>	Cross-border Collaboration in Biotech and Pharma	Commonwealth Hall CD	9 AM – 12 PM 1:30 PM – 5 PM
<b>Track 2</b>	AI and Digital Health	Commonwealth Hall B	1:30 PM – 5 PM
<b>Track 3</b>	Private Pitch	Commonwealth Hall A2	11 AM - 12:30 PM
		Commonwealth Hall A1	2 PM - 4 PM
<b>Track 4</b>	MyBioGate Global Healthcare Innovation Competition	Commonwealth Hall A2	1:30 PM – 5 PM
<b>Track 5</b>	Exhibition and 1:1 meetings	Millennium Hall	9 AM - 12 PM 1:30 PM – 5 PM
<b>Track 6</b>	Reception	Commonwealth Hall CD	5:30 PM - 7 PM

### Millennium Hall



- Exhibition
- 1:1 meeting area

- C1: BioNobleMetals.LLC
- C2: RS Research
- C3: SERAXIS, INC.
- C4: Immunomic Therapeutics, Inc.
- C5: Fox Rothschild LLP
- C6: MORE Health
- C7-C8: Hangzhou Municipal Investment Promotion Bureau
- C9: CUBIO Innovation Center
- C10: MyBioGate
- C11: Orthogon Therapeutics

---

# EVENT CONTENTS

---

TRACK 1 Cross-border Collaboration in Biotech and Pharma .....	01
TRACK 2 AI and Digital Health .....	08
PRESENTING COMPANIES .....	16
TRACK 3 Private Pitch .....	15
TRACK 4 MyBioGate Global Healthcare Innovation Competition .....	18
TRACK 5: Exhibition and 1:1 meetings .....	23
SPONSORS AND PARTNERS .....	25

# TRACK 1

Commonwealth Hall CD

## Cross-border Collaboration in Biotech and Pharma

### TIME

9:00 – 9:40

Opening Remarks

**Keynote: China's Role in Global Life Science & Healthcare**

Katherine Andersen - Head of U.S. Life Science &amp; Healthcare Relationship Banking, Silicon Valley Bank

9:40 – 10:40

**Panel 1: Seeing through the clouds: opportunities and challenges with cross-border investment and partnership**

Kim Nearing – Managing Director, Cedrus Group (Moderator)

Wendy Pan – Partner, Sidley Austin LLP

Dan Zhang – Executive Chairman, Fountain Medical Development Ltd

Mark Tang – Managing Director, Good Health Capital

Herwig Janssen – VP Licensing &amp; Acquisitions Emerging Markets, Janssen Pharmaceutica

Cynthia Cai – Senior Advisor, Northern Light Venture Capital

10:40 – 11:00

Coffee break

11:00 – 12:00

**Panel 2: New wave of innovation: emerging Chinese biotech's overseas strategies**

Brad Loncar – CEO, Loncar Investments (Moderator)

Michelle Chen – VP, Head of Corporate Development, WuXi Biologics

Ping Cao – VP Business Development, Henlius Biotech

Derrick Li – Head of Strategy and Investor Relations, Cellular Biomedicine Group

Weimin Tang – Executive VP Global Business, I-Mab Biopharma

12:00 – 13:30

Lunch

13:30 – 14:10

**Panel 3: Interactions between capital and biotech innovation**

Daniel Chai - Managing Partner, Turret Capital (Moderator)

Andy Li – Founding Partner, BioSense Global LLC

Christian Soschner – CEO, CS Life Science Invest

Eric Wu – Director of Business Development, ReiStone Biopharma

14:10 – 15:00

Company presentation

15:00 – 15:20

Coffee break

15:20 – 16:00

**FEATURED TALK: Building a world-class city in biomedical innovation—Hangzhou**

Jianming Zhao - Deputy Division Director of Hangzhou Municipal Investment Promotion Bureau

16:00 – 17:00

**Panel 4: Partnering opportunities with Chinese pharma**

Bob Ai – Managing Director, Solebury Trout (Moderator)

Lily Zou – CEO, Fosun Pharma USA

Danhui Wang – Founder and Managing consultant, Remedeca Partners LLC

Tom Du – Medical Partner, Shenzhen Share Capital

Jimmy Hao – Partner, Fox Rothschild

Sean Fu - President, Luye Boston R&amp;D LLC, USA

17:30-19:00

Reception

# SPEAKER

## KEYNOTE

### China's Role in Global Life Science & Healthcare



#### Katherine Andersen

Head of Life Science & Healthcare Relationship Banking  
Silicon Valley Bank

Katherine Andersen serves as Head of Life Science & Healthcare Relationship Banking at SVB. She also sits on the Board of Directors for SVB's Joint Venture in China, SPD Silicon Valley Bank. Prior to SVB, Katherine was a Senior Vice President for Wells Fargo Bank leading the Life Sciences business development and relationship management efforts for the New England region. Before that, she was a Director at Wells Fargo Capital Finance focused on front-end business development and underwriting of structured loans. Prior to Wells, she held various positions across mergers and acquisitions, finance, equity derivatives, audit, and management while at Affiliated Managers Group, Merrill Lynch, GE Corporate Audit Staff and GE Capital.

Katherine has a bachelor's degree in finance and economics from Virginia Tech. She has also completed Dartmouth's Tuck Executive Leadership and Strategic Impact Program, Wells Fargo's Transformational Leadership Program, the Program on Negotiation at Harvard Law School and the GE Capital Financial Management Program.

Away from work, Katherine serves on the Finance Advisory Board for Virginia Tech, the Advisory Board for WEST (Women in the Enterprise of Science & Technology), and as Chairperson for the American Cancer Society's Hope Lodge Corporate Council.

## PANEL 1

### Seeing through the clouds: opportunities and challenges with cross-border investment and partnership



#### Kim Nearing (moderator)

Managing Director  
Cedrus Group

Kim has over 20 years of life sciences experience, including in the capacity as a senior operations manager, an investor, an investment banker and a consultant. Currently, as the Managing Director, Head of Life Sciences at the Cedrus Group, a global boutique investment firm headquartered in Hong Kong with offices in Shanghai, and Beijing, Kim is actively engaged in international business and finance activities, particularly in the Greater China and the Gulf Cooperation Council (GCC) regions. She is also the regional leader (NY/NJ/PA) for BayHelix, an invitation-only organization of leaders of Chinese heritage in the global life sciences and healthcare community.



#### Cynthia Cai

Senior Advisor  
Northern Light Venture Capital

Dr. Cai is a senior advisor for Northern Light Venture Capital, a leading venture capital firm for Healthcare, TMT, and Advanced Technologies. She is focused on early-stage investments in the US healthcare segment. Dr. Cai had over 20 years of experience in leadership positions in the Mass Spec. Division for Agilent Technologies, was involved in multiple acquisitions and divestitures, and led a \$500+ million-dollar flagship product development and its global commercialization.

Dr. Cai served as Delaware governor economic advisor, a member of the Board of the Forum for Executive Women (FEW-DE). She has also been a mentor for Wharton EMBA, Tsinghua University Global MBA and Drexel LeBow School of Business for many years.



### Herwig Janssen

Vice President, Licensing & Acquisitions  
Emerging Markets  
Janssen Pharmaceutica

Herwig leads the emerging markets business development activities for Janssen Business Development.

In this position, he leads an experienced and diverse team that negotiates in- and out-licensing activities, technology transfers and acquisitions. The emerging markets are defined as Asia Pacific (except Japan), Latin America, the emerging markets of Europe (including Russia) and Middle east/Africa.

Herwig joined the Johnson & Johnson family of companies in 1984. He has worked in a variety of positions such as clinical research, international marketing and sales. He worked in Business Development for both J&J Medical Devices sector and Consumer sector before joining the Pharmaceutical sector. Herwig studied law at the University of Antwerp, Belgium.



### Mark Tang

Managing Director  
Good Health Capital

Mark Tang is a managing director of Good Health Capital, a healthcare private equity firm with offices in Asia and New York. Mark has over two decades of experience in the field of biotechnology as an entrepreneur, educator, advisor and investor. He previously worked for investment bank PaineWebber/UBS and Morgan Stanley Dean Witter. He was formerly a research associate at Rockefeller University and a biotech director at Rutgers Business School. Mark attended University of California, NYU and Harvard.



### Wendy Pan

Partner, Attorney at Law  
Sidley Austin LLP

Dr. Pan focuses on mergers and acquisitions, technology-based transactions and strategic partnerships, especially in the life sciences industry and in cross-border settings. She has advised private equity firms in leveraged buyouts and has represented financial institutions, technology, media and telecoms (TMT), biopharmaceutical, manufacturing, publishing, electronics companies and retail chains in stock and/or cash acquisitions, mergers, tender offers and going-private transactions. Wendy has advised on mergers and acquisitions transactions with an aggregate value over US\$10 billion. She also represents VC firms and start-up and growth stage companies in venture capital and pre-IPO financings. Wendy represented BGI-Shenzhen in its acquisition of a U.S. Nasdaq company, which is the first successful acquisition of a U.S. public company by a Chinese company.



### Dan Zhang

CEO and Executive Chairman  
Fountain Medical Development Ltd.

Dr. Dan Zhang is the Executive Chairman of Fountain Medical Development Ltd, a clinical CRO with 1700 employees operating in multiple continents.

Prior to Fountain Medical, Dr. Zhang was the Head of Clinical Development and Safety Assessment at Sigma-Tau Research Inc-leading Italian Pharmaceutical Company. He was the vice president at the Quintiles Transnational Corp., the world's largest clinical CRO, and Chairman of Quintiles Medical Development (Shanghai) Company Ltd.

Dr. Zhang is a member of Grant Review committee for National Drug Development Fund of China, and is also a consultant for the CFDA. He is a member of ICH E19 Expert Working Group. He is also chairing the committee of Pharmaceutical R&D, China Pharmaceutical Industry Research and Development Association.

## PANEL 2

### New wave of innovation: emerging Chinese biotech's overseas strategies



**Brad Loncar (moderator)**

CEO  
Loncar Investments

Brad Loncar is an independent biotech investor and analyst, and has managed a biotech-focused family office since 2008. Through Loncar Investments LLC, he uses his research of biotech companies and technologies to develop thematic biotech investment indexes. The Loncar Cancer Immunotherapy Index was launched in March of 2015. It is the only of its kind and consists of 30 companies leading the way in the emerging field of cancer immunotherapy. Mr Loncar previously worked at Franklin Templeton Investments and served in a Senior Advisor role at the U.S. Department of the Treasury. He is one of the most followed biotech commentators on social media and writes biotech commentary at [www.LoncarBlog.com](http://www.LoncarBlog.com). He holds a BA in Finance from the University of Miami.



**Michelle Chen**

VP and Head of Corporate  
Development  
WuXi Biologics

Dr. Michelle Chen is the VP and Head of Corporate Development at WuXi Biologics. In this role, she is responsible for corporate strategy development, M&A, licensing, strategic partnerships, and investment for the company.

Michelle has 20 years of industry experience in drug discovery and development, personalized medicine, and biotechnology development with a strong track record of success in corporate and business development, R&D and commercialization. She has worked for global pharma companies such as Roche, Merck and BioMarin as well as biotech start-ups. Michelle received her Ph.D. in Biochemistry from University of Washington, and did her postdoctoral work at UCSF.



**Derrick Li**

Head of Strategy and Investor Relations  
Cellular Biomedicine Group

Derrick has served as our Head of Strategy and Investor Relations since December 2018. Prior to CBMG, he was at B. Riley FBR, a leading investment bank specializing in working with mid-/small-/micro-cap companies, where he served as Managing Director in their healthcare investment-banking group. From 2013 to 2017, Derrick was a Co-Founder and Managing Director at TPP Healthcare, a leading boutique financial advisory firm, specializing in cross-border transactions between life science companies looking to find investment and partnership opportunities in China. Prior to TPP, Derrick was an Equity Analyst at the Royce Funds, a leading mid-/small-/micro-cap focused mutual fund company owned by Legg Mason. Derrick received dual bachelor degrees in Accountancy and Finance from Villanova University.



**Ping Cao**

VP Business Development  
Shanghai Henlius Biotech

Ping is a chemist by training, obtaining her MS in Organic Chemistry from Michigan State University. Prior to Henlius, she has worked at Tyger Scientific, Ferro, Bristol-Myer Squibb (BMS) and Abzena, and held positions of Director of Sales and Marketing, Sr. Manager of Business Development, Associate Director of Global Manufacturing and Supply Chain, and Sr. Director of Business Development. At Tyger Scientific, Ping increased the business revenue by 600% in 4 years. At BMS, she accomplished significant sales growth, and negotiated and executed 36 technology collaboration deals to expedite the company's drug discovery and development process. As a result, she received the Distinguished Employee Award, Innovation Award, etc. at BMS. At Abzena, she developed and executed business strategy for biologics and ADC that greatly enhanced the company's business growth worldwide.



### Weimin Tang

Global Business Head & Executive VP  
I-Mab BioPharma

Dr. Weimin Tang is currently EVP of I-MAB Biopharma, a clinical stage biotech company focusing on Immunology and Oncology. He served as the Head of US Business Development/Executive Dir. at Jiangsu Hengrui Medicine previously and built Hengrui's global business development team and clinical operation in Princeton, NJ. He was trained as a cancer biologist with a PhD in Biochemistry at Rutgers University. He has accumulated more than 20 years of research and business management experiences with global pharmaceutical companies and biotech companies such as Synaptic Pharmaceutical, BMS, JNJ, Sanofi, Crown Biosciences, Hengrui Medicine and I-MAB Biopharma. Through his industry career, he expanded his function from basic biology to high throughput screening, DMPK and business management.



### Andy Li

Founding Partner  
BioSense Global LLC

Andy has more than 25 years of biomedical research and biopharmaceutical industry experience with proven track records in global drug development in multiple therapeutic areas, alliance management, and business development. He previously held management positions at GSK, Abbott and most recently, Daiichi Sankyo. During his extensive career, Andy worked directly on highly successful projects and products, including HUMIRA and Olmesartan. He also managed and led the development, registration, and commercialization efforts in key markets, including the U.S., Europe, Japan, China, Korea, Taiwan, Brazil and others.

PhD from Albert Einstein College of Medicine and MBA from Duke University.

## PANEL 3

### Interactions between capital and biotech innovation



### Daniel Chai (Moderator)

Managing Partner  
Turret Capital

Dr. Chai has close to 20 years of both private and public investment experience in the global healthcare sector. He founded Turret Capital Management in 2016 and previously served as Portfolio Manager at several leading investment firms including Citadel Investment Group, UBS, and Neuberger Berman. Dr. Chai is an investor and co-founder of Serenikey Therapeutics Inc., a private biotechnology company focused on the treatment of neurological diseases. He was an investor and board member of Nexgen Spine Inc., a private medical devices company focused on the treatment of spinal related disorders, which was acquired by K2M Group Holdings (KTWO). Dr. Chai has a B.S. from the University of Michigan and an M.D. from Columbia University, College of Physicians & Surgeons.



### Christian Soschner

CEO  
CS Life Science Invest

Christian is a business executive with broad experience in corporate development, leadership, mergers & acquisitions, financing and communication. He worked over 25 years in Life Science Pharma Industry and IT, developing and improving business models. In the last 12 years he focused as a CFO on funding and organizing life science companies, as well as structuring deals within the pharmaceutical industry. In his career he participated in raising and managing fundings of more than 400 Million Euros.





### Eric Wu

Director of Business Development  
ReiStone Biopharma

Dr. Eric Wu has over 15 years experiences in business development, consulting, and financial advisory in the pharmaceutical industry cross US and China. He recently joined Reistone BioPharma, a Shanghai based start-up biotech company, as its BD head. Before that, he was a key member of Qilu Pharmaceutical' s global BD team and helped Qilu to launch its BD operation and R&D centers in the US. Before joining Qilu he was the Managing Partner of Jade Advisors LLC, a pharmaceutical consulting firm for US-China transactions. Before that he was the senior VP at Alliance Advisors LLC, an IR firm in Wall Street, in charge of client accounts for China based companies listed in US public market. He also worked as a senior biostatistician at the Pharmacogenomics group at J&J for more than five years. Dr. Wu holds a Ph.D. in Genetics from Texas A&M University and an MBA from NYU Stern School of Business.

## FEATURED TALK

### Building a world-class city in biomedical innovation--Hangzhou



### Jianming Zhao

Deputy Division Director  
Hangzhou Investment Promotion  
Bureau

Zhao Jianming, deputy division director of Hangzhou Investment Promotion Bureau in China, is responsible for the investment promotion of biomedicine industry of the city and participates in drawing a panorama of the biomedicine industry chain. Focusing on the three aspects of "new drug research and development, medical equipment, and medical data" , and clarifying the layout of "One Core, Three Parks and Multiple Dots" , Hangzhou is building an international innovative highland of biomedicine industry.

## PANEL 4

### Partnering opportunities with Chinese pharma



### Bob Ai (moderator)

Managing Director  
Solebury Trout

Bob joined the Trout Group in September 2016 and focuses on the Sino-US cross-border banking and strategic consulting service (mainly licensing) and investor relations. Prior to joining Trout, he was managing director, senior biotech analyst at WallachBeth Capital. Before that, he was the CFO of Aoxing Pharmaceuticals, a NYSE MKT listed Chinese specialty pharmaceutical company. He has also served as Principal in Merlin Nexus and senior equity analysts at Bennett Lawrence and Merlin Biomed Group. Bob received his PhD and MBA from Penn State University and did postdoctoral training at University of Pennsylvania. He has won the prestigious Ray Wu scholarship for outstanding Chinese Student to study abroad. Bob holds Series 7, 63, 79, 86, and 87 securities licenses.



### Tom Du

Chief Consultant at Humphries  
Pharmaceutical Consulting  
Medical Partner at Shenzhen Share  
Capital

Dr. Du is currently the Chief Consultant of Humphries Pharmaceutical Consulting, a global pharmaceutical consulting firm. Trained as a physician and a scientist, He got his medical degree from Tianjin Medical University and his Ph.D. in pathology from McGill University, followed by postdoc training at Harvard University.

Dr. Du has previously worked at US FDA for almost 7 years and reviewed more than 100 INDs and NDAs. he is an expert in botanical drug development in the U.S.

Since leaving the FDA in 2000, Dr. Du has held several crucial roles in the pharmaceutical industry and has helped more than 20 Chinese drug companies to submit ANDA or IND and initiate clinical trials in the U.S.



### Xi-Yong Sean Fu

President  
Luye Boston R&D LLC

Dr. Xi-Yong Fu is the President of Luye Boston R&D LLC. Prior to joining Luye, he was the President of Cureport Inc., a VC backed biotech start-up specialized in liposomal drug delivery technology. Before that, Dr. Fu worked at Merck & Co. for 15 years with extensive experiences in R&D, business development, finance and operational management. He led the integration of global discovery and preclinical R&D network following the landmark \$42B merger between Merck and Schering-Plough. Dr. Fu participated and contributed to over 30 novel drug development programs including ISENTRESS® for HIV/AIDS and ZEPATIER® for chronic HCV infection. Dr. Fu earned his PhD from The Ohio State University and his MBA from the Wharton School of Business.



### Jimmy Hao

Partner  
Fox Rothschild LLP

Dr. Jimmy Hao is a partner in the Intellectual Property Department and a registered patent attorney. He represents companies in the biotech and pharmaceutical industries. Jimmy possesses extensive scientific knowledge, a strong business sense, and a deep understanding of patent, copyright, trademark and trade secrets laws.

Jimmy focuses his practice on patent prosecution, infringement and validity studies, freedom-to-practice studies and design-around analyses. He provides a full range of patent law services to clients, including developing and managing their worldwide patent portfolios, assisting in patent matters and due diligence in connection with strategic alliance, technology transfer transactions & licensing, investment, merger, and acquisition.



### Danhui wang

Managing Partner  
Remedeca Partners LLC

Danhui is a well-versed business leader with 20+ years of experience in life sciences. She previously led Global and U.S. teams at Big Pharma (Abbvie and Johnson & Johnson) and private companies (Upsher Smith and Menarini Group). She served in roles as Development and Commercial Leaders, U.S. Vice President Marketing, and Asia Pacific Director, etc. Currently as Managing Partner of Remedeca Partners, a specialty consultancy, Danhui advises biopharma players on portfolio strategy, business alliances, asset development & commercialization strategy, and go-to-market business models in key geographies. She excels in translating science into compelling business propositions with strategic thinking and operational effectiveness.

Danhui holds an MBA degree from the University of Rochester, and a Bachelor's degree in Economics from Renmin University of China.



### Lily Zou

CEO  
Fosun Pharma USA

Lily Zou is CEO of Fosun Pharma USA, where she is responsible for building Fosun Pharma's commercial operations in the US and growing its US business. Prior to Fosun Pharma, Lily was Executive Director, BD&L at Sandoz Inc., where she executed various deals for generic, 505b2 and biosimilar products, and added over 30 products to Sandoz US portfolio with aggregated annual sales of over \$700M. Prior to Sandoz, Lily worked at top management consulting firm (Bain), large pharmas (Wyeth, Millennium), and smaller biotechs (ArQule, Coley) in various functions including BD&L, strategy, portfolio management and drug discovery.

Lily holds a Ph.D. from Cornell University, an MBA from MIT, and a B.S. from Beijing University.

# TRACK 2

Commonwealth Hall B

## Artificial Intelligence and Digital Health

### TIME

13:30 – 14:00	<p><b>Keynote 1: Impact of AI on the Pharmaceutical Industry - How AI Can Help Reimagine Growth and Innovation in Drug Development Value Chain?</b>            Greg Caressi – SVP, Transformational Health, Frost &amp; Sullivan</p>
14:00 – 14:50	<p><b>Panel A1: New formula for success: how will AI benefit the pharma industry?</b>            Echo Hindle-Yang – CEO, MSQ Ventures (Moderator)            Gunjan Bhardwaj – CEO, Innoplexus AG            Emmanuel Fombu - Global commercial strategy and Digital Innovation Leader, Johnson &amp; Johnson            Alan Jiang – Chief Strategy Officer, XtalPi Inc.            James Lee – Senior Business Development Manager, Atomwise Inc.            Rachel Sha – Vice President, Digital Business Development, Sanofi</p>
14:50– 15:10	Coffee break
15:10 – 15:40	<p><b>Keynote 2: Impact of FDA' s new digital health approach on life science and healthcare</b>            Alexander Gaffney – Sr. Manager, PwC Health Research Institute</p>
15:40 – 16:10	Company presentation
16:10 – 17:00	<p><b>Panel A2: Integration of digital technology in the diagnostics and therapeutics</b>            Bernice Ma – Associate Principal, Evolution Road LLC (Moderator)            Martin Duenas – Founder and CEO, OniX Hub            Alexander Gaffney – Sr. Manager, PwC Health Research Institute            Weiwei Liang – Associate Director BD&amp;L, Sandoz/Novartis            Michael Song – Sr. Manager, MedImmune            Dayong Wang – VP Machine Learning, PathAI</p>

# SPEAKER

## KEYNOTE

### Impact of AI on the Pharmaceutical Industry - How AI Can Help Reimagine Growth and Innovation in Drug Development Value Chain?



#### Greg Caressi

Global Business Unit Leader & Sr Vice President, Transformational Health  
Frost & Sullivan

Greg Caressi is the America business unit leader for the Transformational Health practice at Frost & Sullivan, leading the Life Sciences, Advanced Medical Technology and Connected Health teams. In addition to his leadership responsibilities, Greg spends most of his time working on strategic consulting projects on next-generation healthcare solutions, with a primary focus on connected health and integrated health solutions. Greg served for two years as the Chair of the HIMSS Life Sciences Information Technology Committee, where he led the creation of industry guidance for Good Informatics Practices used by large and small life science companies. Prior to Frost & Sullivan, Greg worked at the Yunnan Finance & Trade Institute in Kunming, China and with the Mabei Taili Group in Taicang, China.



#### Alexander Gaffney

Senior Manager, Health Research Institute  
PwC US

Alexander Gaffney is a senior manager with PwC's Health Research Institute (HRI) and leads HRI's analysis of regulatory and legislative policies impacting the life sciences industry and new entrants.

Prior to joining HRI's regulatory center, Alexander worked for the Regulatory Affairs Professionals Society (RAPS) where he led their regulatory intelligence unit. He has written extensively about the regulation of pharmaceuticals, biotechnology products, medical devices and dietary supplements, and his work has been cited in several congressional reports. He was also the managing editor of Regulatory Focus, RAPS' news publication.

Alexander has his Regulatory Affairs Certification (RAC) in US regulation and is a graduate of Providence College.

## PANEL A1

### New formula for success: how will AI benefit the pharma industry?



#### Echo Hindle-Yang (moderator)

CEO  
MSQ Ventures

Echo is on a mission to make technology accessible by bridging the gap between western companies and Chinese corporations and investors. She has 20 years of experience in cross-border transactions for fortune global companies, such as IBM, Lenovo and J&J. In recent years, making the global movement of the healthcare industry has been her focus. She has been advising hundreds of western pharmaceutical and medical devices companies on advancing their success in China including subsidiaries of Novartis, Daichi, and other top global healthcare companies.

Echo holds an MBA from Duke University and the FINRA Series 7, 63 and 79 securities licenses. She is currently serving on DukeNY Board.



#### Gunjan Bhardwaj

CEO  
Innoplexus

Gunjan Bhardwaj is the Founder and CEO of the Innoplexus group. He was earlier with the Boston Consulting Group and before that the leader of the global business performance think-tank of Ernst & Young and a manager in the German practice with a solution focus on strategy and innovation. He has led projects in strategy, analytics, and technology for various clients in different parts of the world. Gunjan was also a partner, senior-editor, and advisor for a prominent online innovation management journal and was a member of the scientific advisory board of a US based not for profit institute researching in complexity sciences in the healthcare industry.



### Emmanuel Fombu

Global commercial strategy and Digital Innovation Leader  
Johnson & Johnson

Dr. Fombu is an internationally recognized authority on the convergence of digital technologies and healthcare. He is an award winning and best selling author, physician, Keynote speaker, investor, entrepreneur and medical futurist with over 10 years combined experience in clinical medicine, drug development, medical affairs, digital medicine, business development and licensing, research, pragmatic trials and product lifecycle management strategy in biopharmaceutical industry and private equity.

His current focus is on how digital technologies can be leveraged to better measure healthcare related product' s real world effectiveness and value, and also to design more comprehensive disease management systems in partnership with digital health startups, health systems, payers and providers.



### Yide Alan Jiang

Chief Strategy Officer  
XtalPi Inc.

Dr. Jiang as Chief Strategy Officer, Board Director of XtalPi, bears primary responsibility for company's strategy development. He joined XtalPi in 2015 bringing over fifteen years of scientific and management experience, most of it gained in positions of increasing responsibility at Sanofi-Genzyme. He was the director of Asia R&D Strategy and responsible for the development of Asia/China R&D strategy and led cross-functional R&D external collaborations and projects in Asia. Dr. Jiang received his medical degree and doctorate followed by post-doctoral research in hematology and oncology at Harvard Medical School.



### James Lee

Senior Business Development Manager  
Atomwise

James Lee is a Senior Business Development Manager at Atomwise, leading their partnerships with small pharma and biotech companies. Previously, he worked at Genentech in oncology business development and in the commercial organization. Through a career in consulting, James has also partnered with top biopharmaceutical R&D organizations to form an industry collaboration focused in accelerating drug development known as TransCelerate. James has a BAS in Bioengineering and MS in Biotechnology from the University of Pennsylvania where he has authored scientific journal articles. He also holds an MBA from Columbia Business School.



### Rachel Sha

Vice President, Digital Business Development  
Sanofi

Rachel leads a team of Business Development professionals at Sanofi driving transactions from identifying new opportunities to closing deals across therapeutic areas in digital health with the goal of discovering, developing and bringing to market solutions that improve outcomes and experience at reduced costs. She joined Genzyme in 2005 and has held roles with increasing responsibility in Business Development, Corporate Development and Global Marketing & Strategy for Genzyme and Sanofi. Prior to Sanofi, Rachel was a manager at Accenture, where she focused on a broad range of business issues across a diverse set of industries with focus in electronics & high tech in particular. Rachel holds a Bachelor of Science degree in Chemistry from Massachusetts Institute of Technology and an MBA from Harvard Business School.

## PANEL A2

### Integration of digital technology in the diagnostics and therapeutics



#### Bernice Ma (moderator)

Associate Principal  
Evolution Road LLC

Bernice is an experienced digital strategist, having spent 10+ years leading engagements at agencies and strategic consultancies. Bernice is focused on helping clients solve customer and business challenges using a data and insight-driven approach.

Bernice is currently Associate Principal at Evolution Road's Digital Health Practice, a digital consultancy-of-record specialized in maximizing commercial impact of digital health. Specifically, she consults with life science companies to develop their digital health strategy and portfolio, evaluate potential partners, customize and shape digital health solutions, execute and pilot programs, and evaluate impact while minimizing risk.

Bernice earned her BS in Computer Science from Carnegie Mellon University and an MBA in Healthcare Management from the Wharton School at UPenn.



#### Weiwei Liang

Associate Director of BD&L  
Sandoz/Novartis

Mr. Liang aspires to bring new therapeutics to the market and improve people's lives. He has 15+ years' combined technology, finance, commercialization experience in healthcare industry and IT industry in China and US. He is currently Associate Director of Business Development and Licensing at Sandoz division of Novartis in the US, with focus on M&A and in-licensing opportunities in Immunology, Oncology and Digital Therapeutics. Prior to this, he held various management positions with Novartis, Bayer and IBM. He sits on the board of i-LUMEN Scientific, a medical technology company pioneering a new electrical medicine treatment. He received his MBA from Tepper School of Business at Carnegie Mellon University and Bachelor in EE with highest distinction from Beijing University of Technology.



#### Martin Duenas

CEO  
OniX Hub

Martin works at the center of the research science ecosystem including government, private funding organizations, research academic centers, biotech, tech, industry and pharmaceutical companies. Martin is the Founder and CEO of OniX Hub and Ventures. The OniX Hub is a global knowledge enterprise that aggregates research ideas and assets from universities, incubators/accelerators, research parks, pharmaceutical and others. OniX currently has 1M+ ideas/assets from 2K+ universities and 75K+ startups/biotech including funded grants, tech transfer projects, and others. The OniX Hub also provides access to 30M+ publications, 100M+ patents, 300K+ Clinical Trials and 1B+ research news. OniX Ventures will launch 5 funds in different areas: Arthritis, Rare Diseases, Immunology & Inflammation, Food/Nutrition/Agriculture and AI.



#### Michael Song

Senior Manager R&D  
MedImmune

Michael Song is the head of Device Functionality, Safety and Digital Connectivity at MedImmune, a Member of the AstraZeneca Group. In his current role, he oversees device functionality and safety; primary container science and technology; biocompatibility; container closure integrity; and digital connectivity development. Prior to his current role, Michael was head of Device and Package Engineering department at Adello Biologics. He also has held key engineering and toxicology SME positions at Stryker and Kavlico, a member of Schneider Electric. Michael holds a BS in Electrical Engineering from Purdue University and PhD in Neuroscience and Toxicology from Iowa State University.

**Dayong Wang**

VP Machine Learning  
PathAI

Dr. Wang is working in the startup company, PathAI, as the VP Machine Learning. PathAI is building an AI-powered pathology platform to transform the diagnosis and treatment of disease and improve the lives of patients and their families.

Dr. Wang got his bachelor degree from Tsinghua University and his Ph.D. degree from Nanyang Technological University. Currently, he is leading a 20 member machine learning team to work on various projects in three primary aspects: translational research, clinical development, and clinical diagnosis. Before joining PathAI, he worked as a research fellow in BeckLab of Beth Israel Deaconess Medical Center, Harvard Medical School, and won the metastatic breast cancer detection competition (Camelyon16) in the International Symposium on Biomedical Imaging (ISBI).

# PRESENTING COMPANIES

## TRACK 1

### Immunomic Therapeutics, Inc.



Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms. These investigational technologies have the potential to alter how we use immunotherapy for cancer, allergies and animal health. On the heels of two landmark deals in 2015, including an exclusive worldwide license with Astellas Pharma Inc. to explore the use of LAMP-Vax™ for use in the prevention and treatment of allergic diseases which resulted in over \$315M in licensing revenue that year, the company has now focused on the application of its UNITETM platform in oncology. The company has excellent phase I data of GBM cell therapy (currently in P2) and a robust pipeline in oncology. The company is actively searching opportunities in China with a China and SEA focused program (ITI-China).

### Seraxis



Established by pharma and biotech pros, the privately held regenerative medicine company, Seraxis is focused on the development of a cell therapy for insulin-dependent diabetes. Seraxis is now emerging from stealth mode with fully developed, industry-leading tech and a short defined path to clinical testing. Seraxis is opening a new round of capital raise to bring its therapy to the clinic. Seraxis developed a cell therapy/device combination using novel technologies that consistently rescue diabetes in immune-competent models. The development program has brought the company close to IND submission with much of the pre-IND requirements completed. Seraxis proprietary assets include: (1) iPSC line that is unique in its ability to mature into insulin-secreting islets and has 6 issued patents. Seraxis is a factory for pure, transplant-ready cells. (2) Macroencapsulation device that meets the requirements for a practical cell therapy: it is immunoprotective, retrievable, biocompatible and accommodates a therapeutic human dose.

### ALK



ALK is the world leading specialty pharma in Allergy Immunotherapy (AIT) with a 95-year heritage in allergy research and 1.5 million patients currently in treatment with our products. We are present in 32 countries with ~500M USD revenue. The last decade we have pioneered the development of sub-lingual tablet based AIT (SLIT) and invested more than 1 bn\$ in global launch of our FDA approved SLIT portfolio targeting >80% of Respiratory Allergies and Allergic Asthma. Our products have NO PATENT CLIFF. Our lead asset, the House Dust Mite SLIT tablet with brand names ACARIZAX® (EU), ODACTRA™ (US) and MITICURE (JPN) is the only disease modifying treatment option for Allergy and Allergic Asthma.

### MORE Health



MORE Health, a global digital healthcare company, provides patients with access to the best physicians in the world when needed the most: when faced with a critical, potentially life-changing illness. Our collaborative approach to diagnosis puts the patient at the center of the process – empowering them to make informed decisions regarding their own healthcare. Offering all of the benefits of a second opinion, we ensure that the attending doctor and our expert physician specialist are aligned by jointly developing a diagnosis and treatment plan on our proprietary, cloud-based and HIPAA-compliant Physician Collaboration Platform, thus minimizing errors while also resolving potential conflicts regarding the diagnosis and treatment plan development.



## TRACK 2

### 20/20 Genesystems



20/20 Genesystems is a Maryland based company actively commercializing OneTest ([www.OneTestforCancer.com](http://www.OneTestforCancer.com)), a blood test and machine learning algorithm for the early detection of multiple cancers. We have recently achieved scaling revenue in the USA and are getting commercial traction in East Asia, the Middle East, and Europe.

Further details may be found in our recent annual shareholders report: <https://conta.cc/2V8PnR2>.

Earlier this year we closed a Reg. A+ \$5M Series B round and will be looking to raise additional capital concurrent with a public listing of our shares.

# TRACK 3 PRIVATE PITCH (INVITATION ONLY)

## AGENDA

Time	Session
11:00-12:30	Company Pitch
12:30 - 13:30	Lunch Break
14:00-16:00	1-on-1 Partnering Meeting

# PRIVATE PITCH

## FEATURED GUESTS



**Representative:**

Lily Zou, CEO, Fosun Pharma US  
 Larry Cai, Executive Director,  
 Business Development

**Fosun Pharma:** Fosun Pharma regards innovation, research and development as the core driving factor of development and established innovative chemical drugs platform, biologics platform, high-value generic drugs platform and cell-therapy platform. Currently, Fosun Pharma continues to focus on therapeutic areas including oncology, cardiovascular system, central nervous system, blood system, metabolism and alimentary system and anti-infection.



**Representative:**

Hongjian Zhang, Managing Director

**Morningside Group:** Morningside Group was founded in 1986, by the Chan family of Hong Kong, to make private equity and venture capital investments. The group is managed by investment professionals who are entrepreneurial, have deep industry knowledge and are effective in the local environment in which they operate. In addition to its investment activities, Morningside Group is strongly committed to social responsibility.



**Representative:**

Cynthia Cai, Senior Advisor

**Northern Light Venture Capital:** A leading venture capital firm targeting early stage opportunities of innovation in Healthcare, TMT and Advanced Technology. It is established in 2005 and today it has \$4.5 billion dollar managed capital. Leveraging successful investing and entrepreneurial expertise in both China and the United States, the NLVC team looks for partnering with world class entrepreneurs to build world class companies.



**Representative:**

Jenny J. Wang, Director Oncology  
 External Innovation, Global Business  
 Development & Licensing  
 Julie Carnis, Associate Director China  
 & EM

**Sanofi:** Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. We prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. We stand by the few who suffer from rare diseases and the millions with long-term chronic conditions. With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.



**Representatives:**

Herwig Janssen, VP, Licensing  
& Acquisitions Emerging  
Markets

**Luye Pharma:** Luye pharma is an international pharmaceutical company dedicated to the R&D, manufacturing and sale of innovative medications. The company has established R&D centers in China, the U.S. and Europe, with a robust pipeline of 40 drug candidates in China and more than 10 drug candidates overseas. The company currently has a number of new drugs and new formulations in the central nervous system and oncology therapeutic areas under study in the U.S. and Europe. Luye Pharma has reached a high level international standard in advanced drug delivery technologies such as microspheres, liposomes and transdermal drug delivery systems. The company is forward looking, with strategic development of innovative new compounds and antibodies, gene & cell therapies and smart formulations.



**Representative:**

Herwig Janssen, VP, Licensing  
& Acquisitions Emerging  
Markets

**Janssen:** Janssen is committed to creating a future where disease is a thing of the past. The pharmaceutical companies of Johnson & Johnson are working tirelessly to make that future a reality for patients everywhere by fighting sickness with science, improving access with ingenuity, and healing hopelessness with heart. We focus on areas of medicine where we can make the biggest difference: Cardiovascular & Metabolism, immunology, infectious Diseases & Vaccines, Neuroscience, Oncology, and Pulmonary Hypertension.



**Representative:**

Shaoyu Chang, Vice President

**FC Capital:** FC Capital is a cross-border VC/PE fund specialized in healthcare and life science investments. The team operates from its headquarters in Shanghai with additional offices in Taipei and Boston. FC seeks to invest in early stage assets in biopharmaceuticals, medical devices, and healthtech. Current portfolio companies spread across China, Europe, and the United States.



**Representative:**

Jiaying Shi, Vice president  
Xuan Peng, Director

**Huadong Medicine Group:** Huadong is a fully integrated pharmaceutical company focused on discovery, development, manufacturing and commercialization of medicines. Founded in 1993, Huadong Medicine Group is now top 20 pharmaceutical companies in China with annual revenue of 4.5 billion USD. Our products include API, chemical synthetic drugs, TCM and genetic engineering drugs that covers multiple therapeutic areas such as metabolic disease (diabetes), autoimmune disease, digestive disease, cardiovascular, oncology, and infectious disease. In recent years, Huadong Medicine Group has put great efforts on innovative new drug development, with multiple new drugs on our pipeline, we are expecting more collaborations and licensing opportunities to strengthen and expand our exciting pipeline.

**Representative:**

Tom Du, Medical Partner

**Share Capital:** established in Shenzhen in 2007, is the earliest limited partnership professional venture capital institution in China. In the focus area, Share Capital deploys more entrepreneurial projects in the early and mid-stage, and then extend investment in companies with outstanding value to improve the overall return of the fund. Among them, the investment scope of Share Capital in the field of healthcare covers new drug research and development, biotechnology, innovative medical devices, medical and health services and other sub-areas, and formed a new drug research and development, biotechnology as a prominent feature of the investment portfolio.

# TRACK 4

## MYBIOGATE GLOBAL HEALTHCARE INNOVATION COMPETITION

The 2nd China (Jinan) New Growth Drivers International Innovation  
and Entrepreneurship Contest  
American Preliminary

### AGENDA

13:30-13:40	•	Opening Remarks
13:40-14:50	•	Company Presentation
14:50-15:10	•	Break
15:10-17:00	•	Company Presentation
17:00-17:30	•	Break
17:30-19:00	•	Awards Announcement & Reception

# JUDGES



**Frank Luo**  
Managing Director  
Efung Capital



**Tim Xiao**  
Principal  
Delos Capital



**Quang Pham**  
CEO  
Espero BioPharma, Inc.



**Anton Neschadim**  
Associate  
GreenSky Capital



**Andrew Nerlinger**  
Venture Partner  
Bill Wood Ventures



**Mahesh Narayanan**  
CEO  
PepVax, Inc.



**Lalit Gaur**  
Global Head, Business  
Development and Licensing  
Vetoquinol



**Paolo Barbanti**  
CEO  
Pharma & Biotech  
Advisors srl

# PARTICIPATING COMPANIES

## Able Cerebral, LLC



ACL is a bio-pharmaceutical company with products backed by patent granted and patent pending technologies.

We have achieved our first goal via BrainGlucose™ by providing timed release of brain energy to eliminate nightmares, night sweating, hallucinations for Alzheimer' s patients; and to help diabetics to avoid nocturnal hypoglycemia for better sleep and protection from seizure, coma or even death.

We recently started offering fast and sustained release products ChewFull™ and IBShield™ for appetite control / weight loss, and prevention of IBS.

More excitingly, through communications with FDA and friends in biopharmaceutical fields, we are initiating for phase III clinical study inquiry for our delayed and sustained release of energy product as breakthrough NDA for Alzheimer' s disease.

We are also looking for partnership to advance our game changing technology product, a non-invasive medical device, AddMem™.

## AUSPEX DIAGNOSTICS



Auspex is the result of an early collaboration with Dr. William Hait, Director of the Cancer Institute of New Jersey. We had two successful predictions published. Afterward, Dr. Hait joined JNJ and Auspex received Taiwan government grants for follow-up studies in collaboration with the legendary Taiwan Industrial Technology Research Institute and the top hospital VGHTPE. Those studies developed a new robust prediction platform. We then raised a Series A funding to validate the platform. With high confidence in the design, four diagnostics studies were carried out simultaneously. The results were published; all four cases had excellent clinical performances. Our performance was more than double/triple than previously published if a comparison was available, or we had new diagnostics without previous publication.

Currently, Auspex has approval for commercial service in Taiwan; Auspex is collaborating with a top US cancer center to repeat the published Taiwan results to start commercial services in US.

## OcuMedic, Inc



Proprietary timed drug delivery to the eye via a contact lens or clear corneal bandage with extended wear. Ten issued patents with protection thru 2033 and a freedom to operate opinion. Available eye drop market \$16B (CAGR ~8%) Drug Is delivered continuously to the target tissue. The doctor delivers the device thus NO patient involvement solving compliance problems and missed patient dosing.

## Precise Nutrition



Precise Nutrition is building an AI app to help people over 40 eliminate blood pressure, cholesterol, and diabetes medication in 3 months. Currently, prediabetics worsen to diabetic and eventually heart disease patients spending upto \$33,000 a year. We can save upto 80% of these costs for 400 million people globally while boosting their energy levels and making them feel amazing. In addition, our clients have reported feeling 20 years younger, most energetic in years, and with knee pain gone.

Clients are incentivized by an insurance premium reduction of \$1/day. Starting with the chronic disease patient population, we will eventually expand to the 20x larger preventative care population. Precise Nutrition charges insurance companies \$1/day/client and 20% cost savings after reversing a chronic disease. A 5% market penetration would result in annual revenue of \$8.4 billion while enabling insurance companies to save upto 78% on healthcare expenses.

## Tarabios



Tarabios is a spin-off from Koc University, Optic Mems Laboratory. The team is developing a POC/home use blood diagnostic device. Intellectual property rights of the proprietary technology is under protection.

Blood coagulation time (PT) or simply its normalized ratio (INR) is expected to be between 0.8 and 1.2. Lower INR means faster clotting while higher INR means slower clotting. According to medical condition of some patients may require higher levels of INR. Hence frequent and regular testing is required to meet desired INR levels for patients on anti coagulation Therapy. Such frequent testing have a better chance to prevent; stroke, thrombosis and embolism and treat Deep Vein Thrombosis. Tarabios POC / SelfCare PT/INR Diagnostic Device for self-testing platform: • have Novel Fiber Optics based patented Mechanical Measurement System. PT/INR measurement: • Not affected by patient's medication • Independent of Hematocrit Level • High Accuracy according to initial lab tests

## Veriskin, Inc.



Veriskin is a medical device company dedicated to facilitating and improving the accuracy of skin cancer screening. Uncertainty in the initial assessment by non-specialist caregivers leads to failure to detect skin cancer at an early, more treatable stage, malpractice claims due to false negative diagnoses and many unnecessary specialist referrals and biopsies. The TruScore device is a proprietary, non-invasive, low-cost, hand-held unit that aids a non-expert user to rapidly and objectively determine whether a suspect skin lesion is cancerous. The patent pending technology works by detecting pathological angiogenesis which is a well established hallmark of cancer. VeriSkin has developed a proprietary AI algorithm and protocols to achieve 100% sensitivity and 94% specificity in differentiating any type of skin cancer from a variety of benign conditions. The device is intended to be used as a decision support tool for non-specialists, e.g. nurse practitioners or primary care physicians and eventually, consumers.

## Regenerate Therapeutics Inc



Regenerate Therapeutics was incorporated in 2019 after licensing the global unencumbered program and patent from Sumitomo Dainippon pharma around their 1st in class Semaphorin 3a small molecule inhibitor program. Regenerate is developing their recently patented molecules for the treatment neurotrophic ocular surface disease, diabetic macular edema and diabetic nephropathy. The lead program REG-001 is ready to start IND enabling studies for neurotrophic dry eye disease. Regenerate is actively seeking equity financing to initiate IND enabling studies and start human trials in early 2020/2021.


## Pera Labs



We have recently developed SPERMAN, an artificial intelligence (AI) based sperm analysis system which provides solution for time consuming, labor intensive and imprecise sperm assessment procedures in the fertility clinics. SPERMAN helps fertility clinics perform highly accurate sperm assessment in minutes not days. Therefore, it helps reducing infertility treatment time and costs. We do that by deploying deep learning algorithms and our patented microfluidic chip sperm sorting technology making it super easy to accomplish selecting the most healthy sperm with good DNA quality for IVF treatment without harming the sperm. In addition to the benefits of rapid and precise sperm selection, as unique selling point, SPERMAN is also the world's first and the only non-invasive sperm DNA quality analyzer. Recent studies by us and others and several clinical trials showed that dad's DNA quality is associated with healthy birth and early development and the performance of the offspring.



## OmniCyte



We have developed a novel Immuno-Oncology platform technology that selectively activates the cancer immune system (natural killer cells, dendritic cells, CD8 T cells, memory T cells) to target, infiltrate and destroy specific tumor types, without activating unrelated immune elements, which can cause immunotoxic side effects. Our technology can be engineered to safely attack numerous different tumor types. Our first two indications are ovarian cancer and small cell lung cancer.

## Genobank.io



Our patent pending DNA Saliva Kit is the first ethical Saliva DNA extraction kit using Blockchain. It enables users to establish ownership and control over their Multi-Omics data sets. It provides an encrypted & private repository to store, process, share or even sell these data sets based on user's consent. By controlling your sequence in a transparent way, you decide who, how and when to access your profile. You can buy test results of your DNA for early disease identification, sell your profile to interested companies, donate to accelerate scientific discoveries and track a serialized set of your sequence to see how it changes in time (Epigenetics).

## ImmunoRestoration, Inc



ImmunoRestoration's core technology (Immune Conditioning via Activated Innate (autologous) Transfer - ICAIT™) is a novel, integrated dendritic cell-based immunization system to overcome some of the known obstacles facing anti-cancer vaccines: Breakthrough finding: HER-2 pulsed dendritic cell vaccine can eliminate HER-2 expression and impact both invasive breast cancer as well as ductal carcinoma in situ."

Greater than 100 patients have been treated with Ir-Vax since 2004 and in addition to complete responders, there is a strong apparent suppression of disease recurrence in treated patients.

## Athira Pharma, Inc.



Athira Pharma, Inc. is a drug development company striving to improve human health by advancing new therapies for neurodegenerative diseases like Alzheimer's and Parkinson's. Our approach is "first-in-class" with the potential to halt or even reverse degeneration of the nervous system. We are committed to advancing novel and innovative research, developing products that are affordable and accessible in alignment with our strategy focused on the people that we ultimately aim to serve with our therapies. We are mission-driven to restore lives by advancing bold therapies, thoughtfully and urgently.

## Lauren Sciences LLC



Lauren Sciences LLC is a unique New York biotech. Solves greatest medical challenge in treatment of brain diseases – most therapeutic agents, including biologicals, do not cross blood brain barrier (BBB) – with breakthrough innovation, V-Smart®. Creates innovative V-Smart® Platform, proven for non-invasive, dual-targeted, BBB delivery of non-brain penetrant therapeutic agents to central nervous system (CNS). Develops transformative V-Smart® Pipeline of novel V-Smart® Nanomedicines, with de-risked therapeutic agents, for CNS, neurodegenerative, rare/orphan, brain diseases/neurological indications, including ALS, Parkinson's, Chronic Pain, Brain Cancer, Neuro-HIV, Alzheimer's. Achieves: 12 foundation grant awards; 6 pre-clinical pipeline products; 18 peer-reviewed journal publications; 35 research presentations; 7 scientific meeting posters; 10 patent family portfolio estate; 5-member Medical Advisory Board; V-Smart® Nanotechnology license from Ben Gurion University, Israel; Medical Advisory Board, management, mission and motto – "Patients are waiting, but they can't wait patiently®". Lauren Sciences = Dynamic + Sustainable Drug Development Company. V-Smart® = Differentiated + Versatile Superior Platform Technology.

# EXHIBITION

## BioNobleMetals.LLC

Our technology is New material & New business with Antibacterial (killing bacteria) Metal that bonded with organic&inorganic but it is harmless to tissue cell and human body. So that It is used as a dental & medical material, Jewelry fashion metal, and daily life material. (www.BioNoblemetals.com)

- Metal with Antibacterial & Biocompatibility & Nonallergic
  - » All of our metals will have this characteristic. However more specific testing is required.
- Metal bonded with organic & inorganic materials
  - » Complementing the disadvantages of zirconia used as a prosthetic material and periodontal disease caused by prosthetics.
- Metal with beautiful color and brilliance
  - » Complementing Silver alloy with allergenic, coloration, white color.
  - » Complementing Gold alloy with high price.
- Metal bonded with bone and tissue&Plating metal with strong coating force
  - » If we can control it, it could be applied to dental & medical implants, not only to hospitals but also to everyday instruments and tools.

## RS Research



RS Research is a pharmaceutical company developing next generation nanomedicines based on innovative drug delivery platforms for targeted cancer therapy.

4 year old start-up has developed two platforms for targeted delivery with worldwide patents. The platforms carry multiple copies of the drug and a targeting moiety for directing the assembly to tumor tissue. Active targeting of the toxic payload enables reduced side effect profile leading to higher compliance of patients.

First platform is water soluble where the amount of drug loading is determined by the hydrophobicity/hydrophilicity of the drug itself. Second platform consists of a block copolymer where the hydrophobicity of the drug enables formation of micellar constructs in aqueous environment. A second synergistic drug can be loaded

non-covalently.

We currently has a pipeline of 5 drug candidates originated from these 2 platforms. The leading candidate RS-0139 has completed pre-clinical phases and received IND approval to start phase-1 trials, planned for Q3 2019.

## SERAXIS, INC.



The Seraxis mission is to cure insulin-dependent diabetes with cell replacement therapy. Seraxis owns a unique and patent-protected stem cell line and manufacturing process that generates transplant-ready insulin-producing cell clusters. These clusters outperform all competitors' published technology and reverse diabetes in animal models. Seraxis also developed a biocompatible device that enables the transplant of cell clusters to patients without the need for immune suppression. Seraxis is currently raising money to prepare for clinical trials of SR-01, its cell and device combination therapy.

## Immunomic Therapeutics, Inc.



Immunomic Therapeutics, Inc. (ITI) is a privately-held clinical stage biotechnology company pioneering the study of nucleic acid immunotherapy platforms. These investigational technologies have the potential to alter how we use immunotherapy for cancer, allergies and animal health. On the heels of two landmark deals in 2015, including an exclusive worldwide license with Astellas Pharma Inc. to explore the use of LAMP-Vax™ for use in the prevention and treatment of allergic diseases which resulted in over \$315M in licensing revenue that year, the company has now focused on the application of its UNITETM platform in oncology. The company has excellent phase I data of GBM cell therapy (currently in P2) and a robust pipeline in oncology. The company is actively searching opportunities in China with a China and SEA focused program (ITI-China).

## Fox Rothschild LLP



Fox Rothschild LLP is a full-service law firm founded in Philadelphia in 1907. The firm has grown to a 950-lawyer national law firm with 27 offices by focusing on client service and responsiveness, and by attracting bright and creative lawyers who know how to deliver. We give our clients the focus and service of a boutique – with the reach and resources of a national firm.

## MORE Health



MORE Health, a global digital healthcare company, provides patients with access to the best physicians in the world when needed the most: when faced with a critical, potentially life-changing illness. Our collaborative approach to diagnosis puts the patient at the center of the process – empowering them to make informed decisions regarding their own healthcare. Offering all of the benefits of a second opinion, we ensure that the attending doctor and our expert physician specialist are aligned by jointly developing a diagnosis and treatment plan on our proprietary, cloud-based and HIPAA-compliant Physician Collaboration Platform, thus minimizing errors while also resolving potential conflicts regarding the diagnosis and treatment plan development.

## Hangzhou Municipal Investment Promotion Bureau



Hangzhou is characterized by beautiful natural landscapes and rich history and culture, with innovative vitality as the main engine for the city's development. With honors of “the Happiest City of China for 12 consecutive years” , “National Self-dependent Innovation Demonstration

Area” , and “Government efficiency ranks first in the country” , Hangzhou has become the ideal habitat where capital and talents

converge.

In the field of biomedical industry, focusing on the three paths of “new drug research and development, medical equipment and medical data” , and clarifying the layout of “One Core, Three Parks and Multiple Dots” , Hangzhou is committed to creating an innovative highland for the biomedical industry.

## CUBIO Innovation Center



CUBIO is a healthcare incubator and innovative co-working space that not only provides healthcare innovators with office space but also with access to a wide range of diverse resources from human capital, business partners, to investors.

Our mission is to eliminate obstacles faced by innovative companies that are eager to enter China, and help Chinese companies expand and connect with local resources, and to make Houston the epicenter for US-China Cross-border collaboration.

CUBIO puts every effort out to help entrepreneurs and startups looking for an advantageous office location, positioning their businesses with cross-border collaborators in the legal, financial and consultant fields.

## MyBioGate



MyBioGate's mission is to advance healthcare innovation by fostering cross-border collaboration between China and the rest of the world. MyBioGate publishes information and analysis for Chinese-speaking healthcare investors ([www.mybiogate.com](http://www.mybiogate.com)), organizes life science partnering forum China Focus ([events.mybiogate.com](http://events.mybiogate.com)), source and select companies with China market potential through Global Healthcare Innovation Competition ([competition.mybiogate.com](http://competition.mybiogate.com)) and provides customized services to help Chinese corporates and investors source and acquire new products and technologies worldwide.

MyBioGate focuses in sectors with growing market potential in China, including biotechnologies, pharmaceuticals, medical devices and digital health.

# SPONSOR

## GOLD SPONSOR



## SILVER SPONSOR



# PARTNERS





CUBIO is a healthcare incubator and innovative co-working space that not only provides healthcare innovators with office space but also with access to a wide range of diverse resources from human capital, business partners, to investors.

Our mission is to eliminate obstacles faced by innovative companies that are eager to enter China, and help Chinese companies expand and connect with local resources, and to make Houston the epicenter for US-China Cross-border collaboration.

CUBIO puts every effort out to help entrepreneurs and startups looking for an advantageous office location, positioning their businesses with cross-border collaborators and assist with legal, financial and consultant needs.

## 832-491-0069

Call now and enjoy two months free with one-year agreement. Why hesitating, call now!

## For startups and entrepreneurs

- Access to Chinese investors
- Chinese investors validation
- Discover potential China market
- Identify and connect with potential China partners
- Chinese partners due diligence
- China Entry boot camp and services
- Get educated on China business matters, the China Do's, Don'ts and Cautions
- Find potential team members: employee, mentor, vendor, maybe even Co-Founders, in the U.S. and China
- Promoting your business in China, and to our network of companies in the US and Europe
- Connect with upstream and downstream industry players
- Share information and resources with other members
- Member discounted rates at professional organizations
- Discounted rate attending and presenting at the China Focus and Global Healthcare Innovation Competition



# For Chinese investors and pharma companies

- Assist with talent acquisition, access to Chinese world-recognized scientists and leaders from TMC
- Provide reliable sources for U.S. corporation registration, accounting, tax, HR and other related business needs
- Private introduction and pitches from technology and startups in your focused areas
- Identify high-value partnerships, licensing opportunities, or M&A opportunities
- Due Diligence to potential technology and company
- Company and individual background check
- Connect with projects attending China Entry boot camp
- Get educated with local business culture, resources and potential partners
- Receive industry information and resources updates
- Promoting your business in the U.S. and Europe
- Connect with upstream and downstream industry players
- Member discounted rates at professional organizations
- Increase visibility and brand affinity via China Focus and Global Healthcare Innovation and CUBIO local events



**FREE event space, call now to reserve for your next event!**



## Amenities:

- ☑ All-new office furniture
- ☑ Super-fast internet
- ☑ Daily cleaning
- ☑ IT support
- ☑ Onsite staff
- ☑ 24/7 building access
- ☑ Global Network
- ☑ Office phone
- ☑ Coffee & tea break
- ☑ Business class printers
- ☑ Microwave oven
- ☑ Table top oven
- ☑ Mail & package handling
- ☑ Conference rooms
- ☑ Dedicated & complimentary event space
- ☑ Professional and social events
- ☑ Unique common areas
- ☑ Free visitor parking\*
- ☑ Ground parking \$35/car/mo, garage parking \$75/car/mo

## RENT:

- Private office starting at \$795/mo
- Dedicated Desk: \$500/mo/desk
- CUBIO pass: \$300/mo
- Virtual Office \$175/mo

**16,000sf. co-working space, free conference rooms, free 2,000sf. event venue for all professional events. Just ask us!**

**Additional add-on services and incubation/investment opportunities for specific businesses are available, talk to us!**



Fannin Professional Building,  
7707 Fannin Street, Ste. 200,  
Houston, TX 77054



**1-832-491-0069**



info@cubioinnovation.com

<https://cubioinnovation.com>



**CHINA FOCUS @ JPM WEEK**  
2019. Jan. 06  
San Francisco, CA, U.S.



**CHINA FOCUS @ EUROPE VIENNA**  
2019. Mar. 27  
Vienna, Austria



**CHINA FOCUS @ BIO**  
2019. Jun.02  
Philadelphia, PA, U.S.



**CHINA FOCUS @ BWB**  
2019. Sep. 10  
Boston, MA, U.S.



**CHINA FOCUS @ EUROPE HAMBURG**  
2019. Nov.  
Hamburg, Germany



**CHINA FOCUS @JPM WEEK**  
2020. Jan. 12  
San Francisco, CA, U.S.



Scan  
QR code to  
follow us on WeChat  
Web: [events.mybiogate.com](http://events.mybiogate.com) ;  
Email: [info@mybiogate.com](mailto:info@mybiogate.com)

ORGANIZER:  